Rebecca Ahrens Nicklas Shares FDA Interactions on Interventional Genetics with The Rare Disease Community
Rebecca Ahrens Nicklas, Rare disease physician-scientist at the Children’s Hospital of Philadelphia, shared on LinkedIn:
”Excited to share our vision for how we scale personalized gene editing therapies.
We need formal clinical trials to critically evaluate these novel treatments and (hopefully) obtain formal approvals.
One major step to make this happen is regulatory innovation.
We thought it was essential that we share our FDA interactions with the rare disease community so that we can all learn together about how we will build the field of interventional genetics.”
Read the full article in AJHG.
Article: How to create personalized gene editing platforms: Next steps toward interventional genetics
Authors: Rebecca Ahrens Nicklas, Kiran Musunuru
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 11, 2026, 11:00Benjamin YQ Tan on Impacts of Early Cognitive and Psychological Statuses Post-Stroke
-
Jan 11, 2026, 10:46Salvador Payán Pernía: Leukodepletion Reduces Microplastic Burden in Red Blood Cell Concentrates
-
Jan 11, 2026, 10:36Mariasanta Napolitano on Pregnancy and Delivery Outcomes in Women with Hemophilia
-
Jan 11, 2026, 10:19Quick Explanation of Types of Blood Transfusion from John Amako
-
Jan 11, 2026, 06:18Filippo Cademartiri on Why Vascular Health Is Cognitive Health
-
Jan 11, 2026, 06:01Maira Dastgir N on Cannabis-Induced Ischemic Stroke
-
Jan 11, 2026, 05:51Nishant K Mishra on Preventing Post-Stroke Seizures
-
Jan 11, 2026, 05:41Indunil Karunarathna on CSF Xanthochromia in SAH
-
Jan 11, 2026, 05:22Mitchell Elkind on The New York Times Brain Health Challenge: Food Is Brain Medicine!